Effect of asymmetric dimethylarginine (ADMA) on heart failure development

被引：40
作者：
Liu, Xiaoyu [1 ]
Hou, Lei [1 ]
Xu, Dachun [1 ]
Chen, Angela [2 ,3 ]
Yang, Liuqing [2 ,3 ]
Zhuang, Yan [2 ,3 ]
Xu, Yawei [1 ]
Fassett, John T. [4 ]
Chen, Yingjie [2 ,3 ]
机构：
[1] Tongji Univ, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China
[2] Univ Minnesota, Cardiovasc Div, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Lillehei Heart Inst, Minneapolis, MN 55455 USA
[4] Graz Univ, Dept Pharmacol & Toxicol, A-8020 Graz, Austria
来源：
NITRIC OXIDE-BIOLOGY AND CHEMISTRY | 2016年 / 54卷
基金：
中国国家自然科学基金; 美国国家卫生研究院;
关键词：
Nitric oxide; Asymmetric dimethylarginine; Dimethylarginine dimethylaminohydrolase-1; Heart failure; NITRIC-OXIDE SYNTHASE; CARDIOVASCULAR RISK-FACTOR; CHRONIC PRESSURE-OVERLOAD; CORONARY-ARTERY-DISEASE; ORPHAN NUCLEAR RECEPTOR; FARNESOID-X-RECEPTOR; MYOCARDIAL-INFARCTION; URSODEOXYCHOLIC ACID; S-NITROSYLATION; L-ARGININE;
D O I：
10.1016/j.niox.2016.02.006
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthases that limits nitric oxide bioavailability and can increase production of NOS derived reactive oxidative species. Increased plasma ADMA is a one of the strongest predictors of mortality in patients who have had a myocardial infarction or suffer from chronic left heart failure, and is also an independent risk factor for several other conditions that contribute to heart failure development, including hypertension, coronary artery disease/atherosclerosis, diabetes, and renal dysfunction. The enzyme responsible for ADMA degradation is dimethylarginine dimethylaminohydrolase-1 (DDAH1). DDAH1 plays an important role in maintaining nitric oxide bioavailability and preserving cardiovascular function in the failing heart. Here, we examine mechanisms of abnormal NO production in heart failure, with particular focus on the role of ADMA and DDAH1. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码：73 / 81
页数：9
相关论文
共 50 条
  • [41] Asymmetric Dimethylarginine (ADMA) in Pediatric Renal Diseases: From Pathophysiological Phenomenon to Clinical Biomarker and Beyond
    Hsu, Chien-Ning
    Tain, You-Lin
    CHILDREN-BASEL, 2021, 8 (10):
  • [42] Effect of L-arginine on asymmetric dimethylarginine (ADMA) or homocysteine-accelerated endothelial cell aging
    Scalera, Fortunato
    Martens-Lobenhoffer, Jens
    Taeger, Michael
    Bukowska, Alicia
    Lendeckel, Uwe
    Bode-Boeger, Stefanie M.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 345 (03) : 1075 - 1082
  • [43] Metabolism of asymmetric dimethylarginine and its clinical significance
    Erbil, M. Kemal
    Kurt, Yasemin Gulcan
    Yaman, Halil
    Cakir, Erdinc
    Akgul, E. Ozgur
    Cayci, Tuncer
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2012, 37 (01): : 99 - 105
  • [44] Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1)
    Strobel, Joachim
    Mieth, Maren
    Endress, Beate
    Auge, Daniel
    Koenig, Joerg
    Fromm, Martin F.
    Maas, Renke
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2012, 53 (03) : 392 - 400
  • [45] Asymmetric dimethylarginine and coronary collateral vessel development
    Kocaman, Sinan Altan
    Sahinarslan, Asife
    Biberoglu, Gursel
    Hasanoglu, Alev
    Akyel, Ahmet
    Timurkaynak, Timur
    Cengel, Atiye
    CORONARY ARTERY DISEASE, 2008, 19 (07) : 469 - 474
  • [46] Asymmetric dimethylarginine-a determinant of the effect of the high dose Simvastatin
    Vladimirova-Kitova, Lyudmila G.
    Deneva-Koycheva, Tania
    CLINICAL BIOCHEMISTRY, 2010, 43 (10-11) : 843 - 850
  • [47] Invited commentary for asymmetric dimethylarginine (ADMA): Is it a risk factor in the repair of aortic coarctation?
    Do-Nguyen, Chi C.
    Stevens, Randy M.
    Ochoa Gautier, Juan B.
    Throckmorton, Amy
    Mulinari, Leonardo
    JOURNAL OF CARDIAC SURGERY, 2021, 36 (08) : 2741 - 2742
  • [48] Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy
    Shibata, Ryo
    Ueda, Seiji
    Yamagishi, Sho-ichi
    Kaida, Yusuke
    Matsumoto, Yuriko
    Fukami, Kei
    Hayashida, Ayako
    Matsuoka, Hidehiro
    Kato, Seiya
    Kimoto, Masumi
    Okuda, Seiya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (04) : 1162 - 1169
  • [49] Acute effects of 5-methyltetrahydrofolate on endothelial function and asymmetric dimethylarginine in patients with chronic heart failure
    Paul, B.
    Whiting, M. J.
    De Pasquale, C. G.
    Mangoni, A. A.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2010, 20 (05) : 341 - 349
  • [50] Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease
    Wang, J
    Sim, AS
    Wang, XL
    Salonikas, C
    Naidoo, D
    Wilcken, DEL
    ATHEROSCLEROSIS, 2006, 184 (02) : 383 - 388
12345